

Amendments to claims:

This listing of claims will replace all prior versions of claims in the application.

Please cancel claim 73 without prejudice or disclaimer.

Please amend claims 65 to 72 and 76 as follows:

Claims 1 to 64 (canceled).

65. (Currently Amended) An isolated HIV envelope protein capable of inducing the production of a cross-reactive neutralizing anti-serum against multiple strains of HIV-1 *in vitro* comprising an amino acid sequence with at least ~~about~~ ninety-two (92) percent sequence identity to SEQ ID NO: 1.

66. (Currently Amended) The isolated HIV envelope protein of claim 65 wherein the protein comprises an amino acid sequence with at least ~~about~~ ninety-five (95) percent sequence identity to SEQ ID NO: 1.

67. (Currently Amended) The isolated HIV envelope protein of claim 65 wherein the protein comprises an amino acid sequence with at least ~~about~~ ninety-eight (98) percent sequence identity to SEQ ID NO: 1.

68. (Currently Amended) The isolated HIV envelope protein of claim 65 wherein the protein comprises an amino acid sequence with at least ~~about~~ ninety-nine (99) percent sequence identity to SEQ ID NO: 1.

69. (Currently Amended) An isolated HIV envelope protein capable of inducing the production of a cross-reactive neutralizing anti-serum against multiple strains of HIV-1 *in vitro* ~~comprising an amino acid sequence with eighty-five (85) percent sequence identity in the V3 region of SEQ ID NO: 1.~~ wherein the V3 region of the HIV envelope protein comprises amino acids 13 to 25 of SEQ ID NO: 3.

70. (Currently Amended) The isolated HIV envelope protein of claim 69 wherein the protein comprises an amino acid sequence with at least ~~about~~ ninety (90) percent sequence identity in the V3 region of SEQ ID NO: 1.

71. (Currently Amended) The isolated HIV envelope protein of claim 69 wherein the protein comprises an amino acid sequence with at least ~~about~~ ninety-five (95) percent sequence identity in the V3 region of SEQ ID NO: 1.

72. (Currently Amended) The isolated HIV envelope protein of claim 69 wherein the protein comprises an amino acid sequence with at least ~~about~~ ninety-nine (99) percent sequence identity in the V3 region of SEQ ID NO: 1.

73. (Cancelled) ~~The isolated HIV envelope protein of claim 69 wherein the V3 region comprises amino acids 13 to 25 of SEQ ID NO: 3.~~

74. (Previously Presented) The isolated HIV envelope protein of claim 69 wherein the V3 region comprises the amino acid sequence of SEQ ID NO: 3.

75. (Previously Presented) The isolated HIV envelope protein of claim 65 or 69 wherein the protein comprises a cyclic peptide.

76. (Currently Amended) The isolated HIV envelope protein of claim 65 or 69 wherein the protein is at least ~~about~~ 95 amino acid residues in length.

77. (Previously Presented) The isolated HIV envelope protein of claim 65 or 69 wherein the HIV envelope protein is recombinantly produced.

78. (Previously Presented) The isolated HIV envelope protein of claim 65 or 69 wherein the protein is glycosylated at one or more amino acid residues.

79. (Previously Presented) The isolated HIV envelope protein of claim 65 or 69 wherein the HIV envelope protein is synthetically produced.

80. (Previously Presented) The isolated HIV envelope protein of claim 65 or 69 wherein the protein is linked to a second protein.

81. (Previously Presented) The isolated HIV envelope protein of claim 80 wherein the protein is linked to the second protein by a peptide linker.

82. (Previously Presented) An isolated HIV envelope protein comprising the amino acid sequence of SEQ ID NO: 1.

83. (Previously Presented) An isolated HIV envelope protein consisting of the amino acid sequence of SEQ ID NO: 1.

84. (Previously Presented) A composition comprising an isolated HIV-1 envelope protein of any one of claims 65, 69, 82 or 83 and a pharmaceutically acceptable carrier.

85. (Previously Presented) The composition of claim 84 further comprising an adjuvant.

86. (Previously Presented) The composition of claim 84 wherein the composition is suitable for use in humans.

87. (Previously Presented) A method of generating antibodies in a mammal comprising administering the composition of claim 84.

88. (Previously Presented) A method of generating antibodies in a mammal comprising administering the isolated HIV-1 envelope protein of claim 65 or 69.

89. (Previously Presented) The method of claim 88 wherein the mammal is a human.

90. (Previously Presented) The method of claim 88 wherein the antibodies produced are monoclonal.

91. (Previously Presented) The method of claim 90 wherein the mammal is a mouse.

92. (Previously Presented) The method of claim 90 further comprising humanizing the monoclonal antibody.

93. (Previously Presented) The method of claim 88 wherein the antibodies produced are polyclonal.

94. (Previously Presented) The method of claim 88 wherein the mammal is a primate.